Dr. David Koren Provides Perspective to Medscape on Study Presented at IDWeek Annual Meeting Examining Lenacapavir Interactions With Hormonal Contraception

Posters presented at Infectious Disease Week (IDWeek) 2025 Annual Meeting found Lenacapavir does not appear to cause any clinically significant effects in the pharmacokinetics of long-acting hormonal contraceptives or gender-affirming hormone therapy. David Koren, PharmD, MPH, BCIDP, AAHIVP, FIDSA, Infectious Disease Clinical Pharmacist at Temple University Hospital, told Medscape the findings increase options so the right person can be on the right dose of the medication, whether it’s for contraception or gender-affirming therapy.